Omnicell sets October 29 results. Omnicell stock sits 26.90 percent below target

Published on 10/20/2026 at 20:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 2026 revenue rose 7.40 percent to USD 312.21 million. Omnicell stock costs EUR 32.50 on October 20, 2026, versus Nasdaq's USD 35.81 close.

Reporting date and valuation

Omnicell will release third-quarter 2026 results on October 29, 2026.
Second-quarter 2026 revenue rose 7.40 percent to USD 312.21 million.
Omnicell stock costs EUR 32.50 at Lang & Schwarz on October 20, 2026 at 9:03 p.m. CEST.
Wells Fargo maintained a USD 50.00 target on October 14, 2026.

OMCL, US68213N1090, Illustration mit AI erstellt.

Omnicell stock is set for its next major test on October 29, 2026, when the healthcare technology company will release its third-quarter results before the market opens. Omnicell also scheduled an 8:30 a.m. ET conference call for the same date.

At Lang & Schwarz, Omnicell stock was trading at EUR 32.50 on October 20, 2026 at 9:03 p.m. CEST. The Xetra reference close is not used because Omnicell has no substantiated Xetra listing; the Nasdaq quote was USD 36.55 at 2:08 p.m. ET on the same date, compared with a USD 35.81 prior close.

Revenue growth meets the next test

Omnicell reported Q2 2026 revenue of USD 312.21 million, up 7.40 percent from the year-earlier period. Adjusted earnings reached USD 0.94 per share against a USD 0.47 consensus estimate, while revenue exceeded the USD 310.21 million estimate. MarketBeat reported these figures on October 10, 2026.

Stock position and valuation

The Nasdaq quote stood within a USD 29.09 to USD 55.00 52-week range on October 20, 2026. Omnicell's market capitalization was USD 1.7 billion and its price-to-earnings ratio was 43.23 on the same date. The current USD 36.55 quote was 33.55 percent below the 52-week high and 25.64 percent above the low.

What comes with October 29?

Consensus expectations for the third quarter call for revenue of USD 304.45 million and earnings of USD 0.4175 per share. MarketBeat lists October 29, 2026 as the expected reporting date and says Omnicell beat earnings estimates in six of its last eight quarters.

Analyst expectations remain materially above the Nasdaq quote. Markets Insider reported on October 14, 2026 that Wells Fargo maintained a Buy rating and a USD 50.00 target. That target is 36.80 percent above the USD 36.55 Nasdaq quote.

Dates now matter more

The October 29 release will show whether the expected USD 304.45 million revenue level can hold after the USD 312.21 million second-quarter result. For investors, the key comparison is the next quarter's revenue against both the prior-year period and the current estimate.

Omnicell stock at the current level

Omnicell's October 20, 2026 Nasdaq quote of USD 36.55 leaves the shares below the USD 50.00 Wells Fargo target, while the company's second-quarter revenue growth provides a measurable operating benchmark.

The further course of trading is shown by the continuously updated real-time quote of Omnicell stock.